| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | $245.7M-0.8% | $247.8M+154.8% | $97.3M+442.0% | $17.9M+17.8% | $15.2M-9.9% | $16.9M-35.4% | $26.2M+22.0% | $21.4M+24.0% | $17.3M |
| Cost of product sales (excluding amortization of acquired developed technologies) | $503.3M+12.9% | $445.7M+2.3% | $435.6M-19.4% | $540.5M+22.6% | $440.8M+196.0% | $148.9M+16.4% | $127.9M+5.3% | $121.5M+10.3% | $110.2M |
| Selling, general and administrative | $1.81B+30.6% | $1.39B+3.1% | $1.34B-5.2% | $1.42B-2.4% | $1.45B+69.9% | $854.2M+15.9% | $736.9M+7.8% | $683.5M+25.6% | $544.2M |
| Research and development | $782.7M-11.5% | $884.0M+4.0% | $849.7M+43.9% | $590.5M+16.7% | $505.7M+50.8% | $335.4M+11.9% | $299.7M+32.3% | $226.6M+14.2% | $198.4M |
| Intangible asset amortization | $654.7M+4.4% | $627.3M+3.1% | $608.3M+1.5% | $599.2M+14.0% | $525.8M+102.5% | $259.6M-26.8% | $354.8M+76.1% | $201.5M+32.5% | $152.1M |
| Acquired in-process research and development | $947.9M+9378.6% | $10.0M-47.4% | $19.0M-95.7% | $444.1M | $0-100.0% | $251.3M+128.5% | $110.0M | $0-100.0% | $85.0M |
| Total operating expenses | $4.70B+40.1% | $3.35B+3.0% | $3.26B-12.6% | $3.72B+27.4% | $2.92B+47.3% | $1.99B+21.9% | $1.63B+27.7% | $1.28B+17.1% | $1.09B |
| Income (loss) from operations | -$430.2M-160.0% | $716.6M+23.9% | $578.6M+983.0% | -$65.5M-138.5% | $170.3M-55.0% | $378.1M-29.0% | $532.4M-13.4% | $614.8M+16.3% | $528.8M |
| Interest expense, net | -$195.1M+18.1% | -$238.1M+17.7% | -$289.4M-0.4% | -$288.2M-3.4% | -$278.8M-179.6% | -$99.7M-38.0% | -$72.3M+7.9% | -$78.5M-1.0% | -$77.8M |
| Foreign exchange gain (loss) | -$2.6M+68.6% | -$8.2M-193.1% | $8.8M+146.2% | -$19.0M-337.1% | -$4.3M-33.0% | -$3.3M+43.7% | -$5.8M+15.5% | -$6.9M+31.0% | -$10.0M |
| Income (loss) before income tax benefit and equity in loss of investees | -$627.9M-233.5% | $470.4M+57.9% | $297.9M+179.9% | -$372.8M-230.4% | -$112.8M-141.0% | $275.1M-39.4% | $454.3M-14.2% | $529.5M+20.0% | $441.1M |
| Income tax benefit | -$272.4M-198.0% | -$91.4M+23.8% | -$119.9M+24.4% | -$158.6M-173.4% | $216.1M+544.8% | $33.5M+145.8% | -$73.2M-191.3% | $80.2M+267.9% | -$47.7M |
| Equity in loss of investees | $732K-55.9% | $1.7M-44.8% | $3.0M-69.7% | $9.9M+1289.5% | $714K-75.9% | $3.0M-27.6% | $4.1M+85.6% | $2.2M+118.3% | $1.0M |
| Net income (loss) | -$356.1M-163.6% | $560.1M+35.0% | $414.8M+285.1% | -$224.1M+32.0% | -$329.7M-238.2% | $238.6M-54.4% | $523.4M+17.1% | $447.1M-8.4% | $487.8M |
| Basic (in dollars per share) | -$5840.00-164.5% | $9060.00+38.3% | $6550.00+283.0% | -$3580.00+35.1% | -$5520.00-129072.0% | $4.28-53.6% | $9.22+23.8% | $7.45-8.4% | $8.13 |
| Diluted (in dollars per share) | -$5840.00-167.5% | $8650.00+41.8% | $6100.00+270.4% | -$3580.00+35.1% | -$5520.00-130905.7% | $4.22-53.6% | $9.09+24.5% | $7.30-8.3% | $7.96 |
| Weighted-average ordinary shares used in per share calculations - basic (in shares) | $60981000.00-1.4% | $61838000.00-2.3% | $63291000.00+1.2% | $62539000.00+4.8% | $59694000.00+107047.5% | $55712.00-1.8% | $56749.00-5.4% | $59976.00-0.1% | $60018.00 |
| Weighted-average ordinary shares used in per share calculations - diluted (in shares) | $60981000.00-7.6% | $66007000.00-8.4% | $72066000.00+15.2% | $62539000.00+4.8% | $59694000.00+105521.3% | $56517.00-1.8% | $57550.00-6.0% | $61221.00-0.2% | $61317.00 |
| Product sales, net | |||||||||
| Royalties and contract revenues | |||||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.